Titel
Diese Anwendung erfordert Java-Skript.

Bitte aktivieren Sie es in den Browser-Einstellungen.

Project ARSACS biomarker – Unravelling progression biomarkers in ARSACS: a multicenter transmodal combined fluid biomarker…

Basic data

Acronym: ARSACS biomarker
Title: Unravelling progression biomarkers in ARSACS: a multicenter transmodal combined fluid biomarker and magnetic resonance imaging study
Duration: 01/08/2018 to 31/07/2020
Abstract / short description: Autosomal Recessive Spastic Ataxia of Charlevoix Saguenay (ARSACS) is a devastating, incurable neurodegenerative disease now acknowledged as one of the most frequent recessive ataxias worldwide. First translational strategies aiming for disease-modifying treatments are recently emerging. Thus, there is urgent need to establish robust and sensitive outcome parameters for preparing upcoming clinical trials in ARSACS. We here propose a combined transmodal fluid biomarker and neuroimaging study to unravel progression biomarkers for ARSACS, bringing together a unique transatlantic, multi-center consortium which will yield the by far largest, most comprehensive biomarker investigation in ARSACS worldwide, creating combined clinical, biomaterial and multimodal MRI data-sets from 125 ARSACS patients across continents.
Keywords:
ataxia
Ataxie
genetics
Genetik
biomarker
Biomarker
MRT
magnetic resonance tomography, Magnetresonanztomographie
Neurodegeneration
Kleinhirn

Staff

Project managers

Faculty of Medicine
University of Tübingen
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

will be deleted permanently. This cannot be undone.